2,950 Shares in Align Technology, Inc. (NASDAQ:ALGN) Bought by Unique Wealth Strategies LLC

Unique Wealth Strategies LLC purchased a new position in Align Technology, Inc. (NASDAQ:ALGN - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,950 shares of the medical equipment provider's stock, valued at approximately $808,000.

Other institutional investors have also added to or reduced their stakes in the company. EFG Asset Management Americas Corp. lifted its holdings in shares of Align Technology by 3.6% during the fourth quarter. EFG Asset Management Americas Corp. now owns 1,167 shares of the medical equipment provider's stock worth $320,000 after purchasing an additional 41 shares during the period. Dfpg Investments LLC lifted its holdings in shares of Align Technology by 3.3% during the fourth quarter. Dfpg Investments LLC now owns 1,327 shares of the medical equipment provider's stock worth $340,000 after purchasing an additional 42 shares during the period. Richard W. Paul & Associates LLC lifted its holdings in shares of Align Technology by 2.8% during the fourth quarter. Richard W. Paul & Associates LLC now owns 1,669 shares of the medical equipment provider's stock worth $457,000 after purchasing an additional 45 shares during the period. Valley National Advisers Inc. lifted its holdings in shares of Align Technology by 29.7% during the third quarter. Valley National Advisers Inc. now owns 214 shares of the medical equipment provider's stock worth $65,000 after purchasing an additional 49 shares during the period. Finally, Jag Capital Management LLC lifted its holdings in shares of Align Technology by 4.1% during the third quarter. Jag Capital Management LLC now owns 1,258 shares of the medical equipment provider's stock worth $384,000 after purchasing an additional 50 shares during the period. Institutional investors and hedge funds own 88.43% of the company's stock.

Align Technology Stock Down 0.5 %

Shares of ALGN stock traded down $1.48 during trading hours on Friday, hitting $309.02. 737,294 shares of the company's stock were exchanged, compared to its average volume of 636,306. The firm has a market cap of $23.25 billion, a P/E ratio of 50.91, a P/E/G ratio of 5.56 and a beta of 1.65. The firm has a 50 day moving average of $313.38 and a two-hundred day moving average of $270.87. Align Technology, Inc. has a fifty-two week low of $176.34 and a fifty-two week high of $413.20.

Align Technology (NASDAQ:ALGN - Get Free Report) last announced its earnings results on Wednesday, January 31st. The medical equipment provider reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.78 by $0.13. The business had revenue of $956.73 million during the quarter, compared to the consensus estimate of $928.57 million. Align Technology had a return on equity of 14.15% and a net margin of 11.80%. On average, equities analysts forecast that Align Technology, Inc. will post 7.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALGN has been the subject of a number of research reports. SVB Leerink initiated coverage on Align Technology in a report on Monday, February 26th. They set a "market perform" rating and a $310.00 target price for the company. Morgan Stanley lifted their price target on Align Technology from $344.00 to $360.00 and gave the company an "overweight" rating in a research report on Thursday. The Goldman Sachs Group boosted their price target on Align Technology from $197.00 to $225.00 and gave the company a "sell" rating in a report on Friday, February 2nd. Stifel Nicolaus boosted their price target on Align Technology from $350.00 to $400.00 and gave the company a "buy" rating in a report on Thursday, April 18th. Finally, Leerink Partnrs reissued a "market perform" rating on shares of Align Technology in a report on Monday, February 26th. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $341.36.

Insider Activity at Align Technology

In related news, EVP Emory Wright sold 2,524 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total value of $725,523.80. Following the completion of the transaction, the executive vice president now directly owns 709 shares of the company's stock, valued at approximately $203,802.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Emory Wright sold 2,524 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $287.45, for a total value of $725,523.80. Following the completion of the transaction, the executive vice president now directly owns 709 shares of the company's stock, valued at approximately $203,802.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph Lacob sold 15,000 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $303.22, for a total value of $4,548,300.00. Following the completion of the transaction, the director now directly owns 131,994 shares of the company's stock, valued at $40,023,220.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,524 shares of company stock valued at $8,403,924. 0.64% of the stock is owned by insiders.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.